CA3146477A1 - Use of sepiapterin and metabolites thereof to treat radiation exposure - Google Patents
Use of sepiapterin and metabolites thereof to treat radiation exposure Download PDFInfo
- Publication number
- CA3146477A1 CA3146477A1 CA3146477A CA3146477A CA3146477A1 CA 3146477 A1 CA3146477 A1 CA 3146477A1 CA 3146477 A CA3146477 A CA 3146477A CA 3146477 A CA3146477 A CA 3146477A CA 3146477 A1 CA3146477 A1 CA 3146477A1
- Authority
- CA
- Canada
- Prior art keywords
- mir
- subject
- radiation
- administering
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882937P | 2019-08-05 | 2019-08-05 | |
| US62/882,937 | 2019-08-05 | ||
| PCT/US2020/045026 WO2021026247A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3146477A1 true CA3146477A1 (en) | 2021-02-11 |
Family
ID=72148243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3146477A Pending CA3146477A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220273661A1 (https=) |
| EP (2) | EP4454712A3 (https=) |
| JP (2) | JP7642611B2 (https=) |
| CN (2) | CN119837879A (https=) |
| AU (1) | AU2020324435B2 (https=) |
| BR (1) | BR112022002029A2 (https=) |
| CA (1) | CA3146477A1 (https=) |
| DK (1) | DK4009978T3 (https=) |
| ES (1) | ES2994060T3 (https=) |
| FI (1) | FI4009978T3 (https=) |
| HR (1) | HRP20241653T1 (https=) |
| HU (1) | HUE069012T2 (https=) |
| IL (1) | IL290321B1 (https=) |
| LT (1) | LT4009978T (https=) |
| MX (1) | MX2022001535A (https=) |
| PL (1) | PL4009978T3 (https=) |
| PT (1) | PT4009978T (https=) |
| RS (1) | RS66096B1 (https=) |
| SI (1) | SI4009978T1 (https=) |
| SM (1) | SMT202500089T1 (https=) |
| WO (1) | WO2021026247A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| EP3801536B1 (en) | 2018-05-30 | 2024-07-17 | PTC Therapeutics MP, Inc. | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure |
| CN112654356A (zh) | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| EP1696877A4 (en) | 2003-11-13 | 2010-06-09 | Gen Hospital Corp | PROCESS FOR PAIN TREATMENT |
| WO2006055511A2 (en) | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
| TWI359019B (en) * | 2006-08-14 | 2012-03-01 | Merck Eprova Ag | Use of folates for the prevention and treatment of |
| KR20160068776A (ko) | 2013-09-13 | 2016-06-15 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도 |
| WO2016054458A1 (en) | 2014-10-02 | 2016-04-07 | Cytosorbents Corporation | Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| CN110354133A (zh) * | 2019-08-26 | 2019-10-22 | 鞍山市肿瘤医院 | 四氢生物蝶呤的应用及药物 |
-
2020
- 2020-08-04 IL IL290321A patent/IL290321B1/en unknown
- 2020-08-05 CA CA3146477A patent/CA3146477A1/en active Pending
- 2020-08-05 EP EP24187395.9A patent/EP4454712A3/en active Pending
- 2020-08-05 CN CN202411691224.1A patent/CN119837879A/zh active Pending
- 2020-08-05 FI FIEP20758407.9T patent/FI4009978T3/fi active
- 2020-08-05 PL PL20758407.9T patent/PL4009978T3/pl unknown
- 2020-08-05 CN CN202080069308.5A patent/CN114555090B/zh active Active
- 2020-08-05 EP EP20758407.9A patent/EP4009978B1/en active Active
- 2020-08-05 HR HRP20241653TT patent/HRP20241653T1/hr unknown
- 2020-08-05 AU AU2020324435A patent/AU2020324435B2/en active Active
- 2020-08-05 HU HUE20758407A patent/HUE069012T2/hu unknown
- 2020-08-05 WO PCT/US2020/045026 patent/WO2021026247A1/en not_active Ceased
- 2020-08-05 ES ES20758407T patent/ES2994060T3/es active Active
- 2020-08-05 PT PT207584079T patent/PT4009978T/pt unknown
- 2020-08-05 SI SI202030521T patent/SI4009978T1/sl unknown
- 2020-08-05 RS RS20241189A patent/RS66096B1/sr unknown
- 2020-08-05 LT LTEPPCT/US2020/045026T patent/LT4009978T/lt unknown
- 2020-08-05 SM SM20250089T patent/SMT202500089T1/it unknown
- 2020-08-05 US US17/631,995 patent/US20220273661A1/en active Pending
- 2020-08-05 MX MX2022001535A patent/MX2022001535A/es unknown
- 2020-08-05 BR BR112022002029A patent/BR112022002029A2/pt unknown
- 2020-08-05 JP JP2022507561A patent/JP7642611B2/ja active Active
- 2020-08-05 DK DK20758407.9T patent/DK4009978T3/da active
-
2025
- 2025-02-26 JP JP2025029508A patent/JP2025098011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020324435B2 (en) | 2026-03-19 |
| IL290321B1 (en) | 2026-04-01 |
| PT4009978T (pt) | 2024-11-05 |
| RS66096B1 (sr) | 2024-11-29 |
| EP4009978B1 (en) | 2024-09-25 |
| EP4454712A2 (en) | 2024-10-30 |
| EP4454712A3 (en) | 2025-01-01 |
| SMT202500089T1 (it) | 2025-03-12 |
| IL290321A (en) | 2022-04-01 |
| CN119837879A (zh) | 2025-04-18 |
| MX2022001535A (es) | 2022-03-04 |
| PL4009978T3 (pl) | 2025-02-24 |
| JP2022543655A (ja) | 2022-10-13 |
| FI4009978T3 (fi) | 2024-11-01 |
| ES2994060T3 (en) | 2025-01-16 |
| AU2020324435A1 (en) | 2022-02-24 |
| DK4009978T3 (da) | 2024-10-14 |
| US20220273661A1 (en) | 2022-09-01 |
| WO2021026247A1 (en) | 2021-02-11 |
| LT4009978T (lt) | 2024-11-25 |
| HRP20241653T1 (hr) | 2025-04-25 |
| JP2025098011A (ja) | 2025-07-01 |
| BR112022002029A2 (pt) | 2022-06-07 |
| HUE069012T2 (hu) | 2025-02-28 |
| SI4009978T1 (sl) | 2025-03-31 |
| CN114555090A (zh) | 2022-05-27 |
| EP4009978A1 (en) | 2022-06-15 |
| CN114555090B (zh) | 2024-12-17 |
| JP7642611B2 (ja) | 2025-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020324435B2 (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| EP3054952B1 (en) | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer | |
| EP1807083B1 (en) | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
| Wang et al. | The roles of oxidative stress and Beclin-1 in the autophagosome clearance impairment triggered by cardiac arrest | |
| JP2018507244A (ja) | 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬 | |
| US20090318534A1 (en) | Methods and compositions for the treatment of skin diseases and disorders | |
| ES3053975T3 (en) | Benzoxazinone compounds as klk5/7 dual inhibitors | |
| AU2019354784B2 (en) | Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases | |
| JP2019510743A (ja) | 痛風、ざ瘡及び糖尿病の予防又は治療のためのジメチルフマレート（ｄｍｆ） | |
| HK40118407A (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| HK40075560A (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| HK40075560B (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| EA048135B1 (ru) | Применение сепиаптерина и его метаболитов для лечения радиационного облучения | |
| EA052521B1 (ru) | Применение сепиаптерина и его метаболитов для лечения радиационного облучения | |
| CN111166756B (zh) | 20（S）-人参皂苷-Rg3在逆转胶质瘤细胞对化疗药物的耐药性中的用途 | |
| CN101432000B (zh) | 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂*衍生物的预防剂或治疗剂 | |
| JP7854389B2 (ja) | Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物 | |
| EP4545076A1 (en) | Lat1 selective inhibitors for use in the treatment of adverse ventricular -remodelling and of heart failure | |
| RU2831430C1 (ru) | Соединения бензоксазинона в качестве двойных ингибиторов klk5/7 | |
| WO2022195579A1 (en) | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases | |
| HK40059411A (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| HK40059411B (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250723 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250723 |